(Lance D Johnson) In January of 2020, a little-known company named Moderna got access to the genomic sequences of SARS-CoV-2 isolates. These sequences were quickly used to develop mRNA-1273, an mRNA vaccine that encodes SARS-CoV-2 spike proteins in human cells.